A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C
Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106 or 9x106 U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of tre...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1997-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1997/454395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550034699190272 |
|---|---|
| author | Masafumi Komatsu Tsuyoshi Ono Ko Nakajima Itaru Toyoshima Mitsuro Chiba Osamu Masamune Shunji Ohkubo Tsukasa Yoshida Hitoshi Yagisawa Kanji Komatsu Hideki Wakamatsu Nobuo Yamada Hiroyuki Watanabe Tsuyoshi Mukojima Mitsuo Goto |
| author_facet | Masafumi Komatsu Tsuyoshi Ono Ko Nakajima Itaru Toyoshima Mitsuro Chiba Osamu Masamune Shunji Ohkubo Tsukasa Yoshida Hitoshi Yagisawa Kanji Komatsu Hideki Wakamatsu Nobuo Yamada Hiroyuki Watanabe Tsuyoshi Mukojima Mitsuo Goto |
| author_sort | Masafumi Komatsu |
| collection | DOAJ |
| description | Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106 or 9x106 U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of treatment, followed in both cases by 6x106 U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFNα-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus. |
| format | Article |
| id | doaj-art-df8e7ad5bcd94301af26af18cd67bada |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1997-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-df8e7ad5bcd94301af26af18cd67bada2025-02-03T06:07:58ZengWileyCanadian Journal of Gastroenterology0835-79001997-01-0111757958210.1155/1997/454395A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis CMasafumi Komatsu0Tsuyoshi Ono1Ko Nakajima2Itaru Toyoshima3Mitsuro Chiba4Osamu Masamune5Shunji OhkuboTsukasa Yoshida6Hitoshi Yagisawa7Kanji Komatsu8Hideki Wakamatsu9Nobuo Yamada10Hiroyuki Watanabe11Tsuyoshi Mukojima12Mitsuo Goto13First Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Hiraka General Hospital, Yokote, JapanSecond Department of Internal Medicine, Akita City Hospital, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanDepartment of Gastroenterology, Honjyo Daiici Hospital, Honjyo, JapanDepartment of Gastroenterology, Honjyo Daiici Hospital, Honjyo, JapanDepartment of Gastroenterology, Yuri Kumiai General Hospital, Honjyo, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanFirst Department of Internal Medicine, Akita University School of Medicine, Akita, JapanSixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106 or 9x106 U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of treatment, followed in both cases by 6x106 U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFNα-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus.http://dx.doi.org/10.1155/1997/454395 |
| spellingShingle | Masafumi Komatsu Tsuyoshi Ono Ko Nakajima Itaru Toyoshima Mitsuro Chiba Osamu Masamune Shunji Ohkubo Tsukasa Yoshida Hitoshi Yagisawa Kanji Komatsu Hideki Wakamatsu Nobuo Yamada Hiroyuki Watanabe Tsuyoshi Mukojima Mitsuo Goto A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C Canadian Journal of Gastroenterology |
| title | A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C |
| title_full | A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C |
| title_fullStr | A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C |
| title_full_unstemmed | A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C |
| title_short | A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C |
| title_sort | multicentre randomized controlled trial of recombinant interferon alpha 2a in the treatment of patients with chronic hepatitis c |
| url | http://dx.doi.org/10.1155/1997/454395 |
| work_keys_str_mv | AT masafumikomatsu amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsuyoshiono amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT konakajima amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT itarutoyoshima amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT mitsurochiba amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT osamumasamune amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT shunjiohkubo amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsukasayoshida amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hitoshiyagisawa amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT kanjikomatsu amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hidekiwakamatsu amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT nobuoyamada amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hiroyukiwatanabe amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsuyoshimukojima amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT mitsuogoto amulticentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT masafumikomatsu multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsuyoshiono multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT konakajima multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT itarutoyoshima multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT mitsurochiba multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT osamumasamune multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT shunjiohkubo multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsukasayoshida multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hitoshiyagisawa multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT kanjikomatsu multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hidekiwakamatsu multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT nobuoyamada multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT hiroyukiwatanabe multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT tsuyoshimukojima multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc AT mitsuogoto multicentrerandomizedcontrolledtrialofrecombinantinterferonalpha2ainthetreatmentofpatientswithchronichepatitisc |